Omega Therapeutics Unveils Key Updates in Leadership and Research

Omega Therapeutics has announced several key updates, including appointing Dr. Kaan Certel as CEO, succeeding Mahesh Karande, and Dr. Jennifer Nelson as Chief Scientific Officer. Dr. Certel, previously Omega’s Chief Business Officer, brings over two decades of leadership in biopharma and academia, while Dr. Nelson has been instrumental in advancing innovative therapeutics.

The company is prioritizing programs targeting obesity, regenerative medicine, and metabolic disorders, leveraging its epigenomic control technology. Collaboration with Novo Nordisk on an obesity treatment using trans-differentiation technology is progressing, alongside advancements in liver disease and metabolic indications.

Omega also shared topline Phase 1 data from its MYCHELANGELO™ trial, showing targeted epigenomic modulation, safety, and promising disease control in hepatocellular carcinoma patients. The company remains focused on advancing these innovative therapies while seeking strategic partnerships to accelerate development.